Project Grant R34CA283349
Award Date
9/13/24
Completion Date
11/30/26
Dollars Obligated
$327K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Columbia, MO 65211, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...
The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The...
The National Cancer Institute (NCI) awarded a $680,433 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to The Regents of the University of California, San Francisco (UCSF) to conduct a multi-year research project titled "Multimodality Spatial Analysis in Prostate Cancer to Improve Prognostic Estimation and Cast Light into the Black Box of Pathology Artificial Intelligence Algorithms." The goal of this research is to apply cutting-edge spatial proteogenomic...
The National Cancer Institute (NCI) awarded a $1,338,648 project grant under CFDA Program 93.393, Cancer Cause and Prevention Research, to the University of Pittsburgh. The grant will fund a hybrid effectiveness-implementation trial of the CARES intervention, which aims to improve health-related quality of life for cancer patients experiencing depression, pain, and fatigue. The study will evaluate the effectiveness of CARES in a real-world setting, conduct an implementation evaluation, and...
This $1,050,000 Cooperative Agreement award, issued by the National Center for Chronic Disease Prevention and Health Promotion, is funded under the Centers for Research and Demonstration for Health Promotion and Disease Prevention (CFDA 93.135) program. The award, with a performance period from September 30, 2024 to September 29, 2027, supports research led by the University of California, San Francisco (UCSF) on patient perspectives regarding relabeling and pathology reporting for Grade Group 1...
The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $613,220 project grant to the University of Southern California (USC) to investigate the contribution of germline copy number variations (CNVs) to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The 5-year project, starting February 1, 2025, will combine imputation and sequencing-based approaches to comprehensively assess CNVs...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $402,401 to the University of Missouri System to conduct a pilot study on the feasibility and impact of a metacognitive strategy training (MCST) intervention for women with cancer-related cognitive impairment (CRCI) following breast cancer treatment. The study aims to examine the effects of MCST on cognitive performance, frontoparietal neural functioning, and functional...
This $172,197 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to establish and refine processes to facilitate clinical trials in cancer interception (active cancer prevention) at the University of Kansas Cancer Center (KUCC). Key objectives include: Hiring project navigators to support study approvals for principal investigators in non-oncology departments outside KUCC Training research coordinators in cancer prevention trial processes...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $182,236 to New York University School of Medicine to adapt and pilot test an evidence-based sexual health communication skills training intervention for prostate cancer patients. The key products and services to be delivered include: Conducting focus groups with prostate cancer patients and interviews with providers to identify barriers and facilitators to patient-provider communication...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $358,000 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to Brigham & Women's Hospital Inc. The project, titled "Nonresponse of Patient-Reported Outcomes in Routine Cancer Care," aims to characterize and address the issue of nonresponse in patient-reported outcome (PRO) data collection in routine cancer care. The project will (1) characterize nonresponse patterns...